PKUMDL-WQ-2101
CAS No. : 304481-72-9
| Size | Price | Stock |
|---|---|---|
| 5mg | $50 | In-stock |
| 10mg | $80 | In-stock |
| 25mg | $170 | In-stock |
| 50mg | $290 | In-stock |
| 100mg | $500 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-123269 |
| M.Wt: | 317.25 |
| Formula: | C14H11N3O6 |
| Purity: | >98 % |
| Solubility: | DMSO : 116.67 mg/mL (ultrasonic) |
PKUMDL-WQ-2101 is a non-NAD+-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity[1].
IC50 & Target:IC50: 34.8 μM (PHGDH)[1]
In Vitro:PKUMDL-WQ-2101 (72 hours) shows dose-dependent suppression effects on the cell viability at micromolar concentrations, with good selectivity for PHGDH amplified breast cancer cell lines. The antitumor activities of PKUMDL-WQ-2101 in the two PHGDH amplified breast cancer cell lines (MDA-MB-468 and HCC70) are 7.70 μM and 10.8 μM, respectively[1].
PKUMDL-WQ-2101 (2.5-40 μM; 24 hours) causes cell cycle arrest in MDA-MB-468 cells[1].
PKUMDL-WQ-2101 (37 μM; 24 hours) decreases de novo serine synthesis and metabolism downstream of the serine synthesis pathway, with effects comparable to PHGDH genetic deletion[1].
In Vivo:PKUMDL-WQ-2101 (5-20 mg/kg; i.p; daily; for 30 days) exhibits substantial inhibitory effects on MDA-MB-468 xenografts[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- PKUMDL-WQ-2101
- Cat. No.:
- HY-123269
- Quantity:
Your information is safe with us.